ArticleEClinicalMedicine2026
AAV9-mediated GAA gene therapy following enzyme replacement therapy discontinuation in children with infantile-onset Pompe disease.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While our previous research showed that a single infusion of recombinant AAV9-mediated Methods: In this investigator-initiated, single-arm trial (ChiCTR2200065664), six children with IOPD aged 12.5-50.8 months-all having previously received 10-98 cycles of ERT-were enrolled and administered a single intravenous infusion of AAV9-mediated gene therapy. Over a 12-month period, the following outcomes were evaluated: primary efficacy endpoints (gross motor function, and cardiac structure and function); secondary efficacy endpoints (ventilator-free survival, and the proportion of patients who showed improvement at the end of the trial); exploratory endpoints (IOPD-related skeletal muscle pathological changes); safety and tolerability endpoints; and immunogenicity assessment endpoints. Findings: The intervention was generally well tolerated, with a low incidence of grade ≥3 adverse events (2.31 events per person-time). All six patients remained ventilator-free over the one-year observation period (one patient required transient ventilatory support for pneumonia). However, lung function and cardiac structure showed no further improvement after gene therapy. All children (patient 4 was not documented due to early withdrawal from the study) maintained sustained growth and development throughout follow-up, and overall quality of life showed a trend of improvement (PedsQL 3.0 NMM). During the study period, patient 1 achieved standing with assistance and crawling; patient 2 achieved standing and walking without assistance; and patient 3 achieved walking and sitting without assistance. Muscle biopsies from the three patients revealed relatively high GAA enzyme activity and reduced glycogen accumulation. Interpretation: These preliminary findings suggest that AAV9-mediated GAA gene therapy may reduce reliance on ERT and is associated with improvements in muscle histopathology among biopsied participants. Funding: 2023YFC3403300; Z231100004823022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.